5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS)

Inhye E. Ahn, Matthew S. Davids, Jennifer R. Brown et al.|Hematological Oncology|2023

Cited by 1